Core Insights - The company reported annual revenue of approximately RMB 700 million to 720 million for the period ending December 31, 2025, representing a year-on-year growth of about 13.7% to 17.0% [1] Group 1: Revenue Growth - The continuous revenue growth is primarily attributed to the strong performance of all three major product lines in the neurointervention business and the expanding market share in the transcatheter aortic valve replacement (TAVR) market, driven by the successful launch of the high-end TaurusMax® 3D adjustable TAVR system [1] - All three major product lines in neurointervention recorded robust revenue growth, reflecting strong performance of their core products [1] Group 2: Product Performance - The vascular access products saw revenue growth, benefiting from the increasing sales of the high-performance DCwire® microcatheter, which significantly enhanced market share [1] - The hemorrhagic product line experienced revenue growth due to the successful launch of the YonFlow® flow-directed mesh stent [1] - The ischemic product line's revenue growth was mainly driven by increased sales of the Syphonet® thrombectomy stent and Tethys AS® thrombectomy catheter [1] Group 3: TAVR Market Expansion - The commercialized TAVR product portfolio was adopted in approximately 130 new hospitals during the reporting period, covering over 780 hospitals as of December 31, 2025 [2] - A total of approximately 3,900 units were implanted during the reporting period, representing a year-on-year growth of 14.4%, significantly exceeding the overall market growth rate [2] - The company anticipates full commercialization in the Chinese aortic regurgitation market following the approval of the registration application for the TaurusTrio® transcatheter aortic valve system by the National Medical Products Administration in December 2025 [2]

Core Viewpoint - The company, Peijia Medical-B (09996.HK), anticipates a revenue of approximately RMB 700 million to RMB 720 million for the fiscal year ending December 31, 2025, representing a year-on-year growth of about 13.7% to 17.0% compared to RMB 615.5 million in 2024, driven by strong performance across its neurointerventional product lines and an expanding market share in the TAVR segment [1]. Group 1: Revenue Growth Drivers - The neurointerventional business has shown robust revenue growth across all three product lines, reflecting strong performance of core products [2]. - Revenue growth in vascular access products is primarily attributed to the increasing sales of the high-performance DCwire® microcatheter, which has significantly enhanced market share [2]. - The hemorrhagic products segment has benefited from the successful launch of the YonFlow® flow-directed stent, contributing to revenue growth in this product line [2]. - Revenue growth in ischemic products is mainly due to increased sales of the Syphonet® thrombectomy stent and Tethys AS® thrombectomy catheter, with overall revenue stability despite price reductions following the implementation of volume-based procurement [2]. Group 2: TAVR Market Expansion - The company's commercialized TAVR product portfolio, including TaurusOne®, TaurusElite®, and TaurusMax® systems, has been adopted by approximately 130 new hospitals, reaching a total of over 780 hospitals by December 31, 2025 [2]. - A total of approximately 3,900 TAVR procedures were implanted during the reporting period, marking a year-on-year growth of 14.4%, significantly outpacing the overall market growth rate [3]. - The company expects to fully commercialize the TaurusTrio® transcatheter aortic valve system in the Chinese aortic regurgitation market following its approval by the National Medical Products Administration in December 2025 [3].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或 因依賴該等內容而引致的任何損失承擔任何責任。 Peijia Medical Limited 沛嘉醫療有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股 份 代 號：9996） 自願性公告 截至2025年12月31日止年度的未經審核營運數據 本公告由沛嘉醫療有限公司（「本公司」，連同其附屬公司統稱「本集團」）自願 刊發，以向本公司股東及潛在投資者提供有關本集團最新業務及產品開發進 展的最新資料。 本公司董事（「董事」）會（「董事會」）欣然宣佈本集團截至2025年12月31日止年度 （「報告期間」）的若干未經審核營運數據及比較數據載列如下。 1月1日至12月31日期間 | 2025年 | 2024年 | 變動 | | --- | --- | --- | | 人民幣百萬元 | 人民幣百萬元 | % | – 1 – 神經介入所有三大產品線均錄得穩健的收入增長，反映其各自核心產品的強 勁表現。主要驅動因素概述如下： 於報告期間，本 ...

Core Viewpoint - Peijia Medical Limited reported a total revenue of RMB 353 million for the six months ending June 30, 2025, representing a 17.3% increase compared to the same period in 2024, with stable revenue contributions from TAVR and neurointerventional products [1] Financial Summary - The sales revenue from TAVR-related products increased by 24.0% to RMB 162 million, driven by an enhanced market share in China's TAVR market and a shift towards newly launched high-end products [2] - Neurointerventional products saw a 12.2% increase in sales revenue to RMB 192 million, supported by deeper market penetration of existing products and the successful launch of the YonFlow® stent [2] - The overall operating loss narrowed by 19.4% to RMB 68.32 million, with core business net loss significantly reduced by 52.4% to RMB 30.72 million [2] Cost Control and Efficiency - The TAVR business achieved commercial profitability for the first time, generating a profit of RMB 29.09 million, with sales and distribution expenses decreasing by 8.3% to RMB 100 million [4] - R&D expenses for the TAVR division decreased by 17.2% to RMB 54.2 million, primarily due to the completion of major clinical trials [4] - The management expenses slightly increased by 2.8% to RMB 50.98 million, mainly due to depreciation costs of a new headquarters [4] Innovation and Product Development - Three key in-development products are entering the registration application phase, including the TaurusTrio™ TAVR system, TaurusNXT® TAVR system, and GeminiOne® TEER system, with expected approvals between late 2025 and mid-2026 [5] - The DCwire® microguidewire and YonFlow® stent are highlighted as strong performers in the neurointerventional segment, with the former's sales revenue increasing nearly 140% [9] - The company is preparing for the market launch of the TaurusTrio™, which is expected to significantly enhance its competitive position in the AR valve market [5] Operational Efficiency - The neurointerventional division's profit increased by 42.4% to RMB 40.9 million, supported by effective cost control and operational efficiency measures [11] - The company has successfully integrated lean production and supply chain management to mitigate revenue pressures from centralized procurement [11] - The overall strategy emphasizes innovation-driven growth, operational efficiency, and maintaining market leadership in cardiovascular disease treatments [11]

Core Insights - The company reported a revenue of approximately 353 million yuan for the first half of 2025, representing a year-on-year growth of 17.3% [1] - Gross profit reached 248 million yuan, with a year-on-year increase of 13.14% [1] - Research and development expenses amounted to about 116 million yuan, reflecting a year-on-year growth of 15.1% [1] Revenue Growth Drivers - The sustainable revenue growth is primarily attributed to strong sales growth in the transcatheter valve therapy and neurointervention businesses [1] - Sales revenue from TAVR-related products increased by 24.0% to 162 million yuan, driven by market share gains in the Chinese TAVR market and a shift towards newly launched high-end products [1] - Total terminal implants exceeded 2,050 units, marking a year-on-year growth of approximately 18.8%, surpassing market growth [1] Neurointervention Product Performance - Sales revenue from neurointervention products rose by 12.2% to 192 million yuan, with key drivers including deeper market penetration of existing products and the successful launch of the newly approved YonFlow® blood flow-directed stent [1] - The DCwire® microcatheter significantly expanded market share with a revenue growth of nearly 140% during the reporting period [2] - The YonFlow® blood flow-directed stent received regulatory approval in April 2025 and has been actively marketed, achieving its first commercial implant by June 2025 [2]

Core Viewpoint - Peijia Medical-B (09996.HK) reported a revenue of RMB 353.4 million for the six months ending June 30, 2025, representing a 17.3% increase compared to the same period in 2024, driven by strong sales growth in both transcatheter aortic valve replacement (TAVR) and neurointerventional products [1] Revenue Composition - Revenue composition remained stable, with 45.7% from TAVR-related product sales and 54.3% from neurointerventional product sales, compared to 43.3% and 56.7% respectively in the first half of 2024 [1] TAVR Product Sales - TAVR-related product sales increased by 24.0% year-on-year to RMB 161.6 million, driven by market share gains in China's transcatheter aortic valve market and a shift towards newly launched high-end products [1] - Total implantations exceeded 2,050 units during the reporting period, reflecting an approximate 18.8% year-on-year growth, surpassing market growth [1] Neurointerventional Product Sales - Neurointerventional product sales rose by 12.2% year-on-year to RMB 191.8 million, with key drivers including deeper market penetration of existing products (such as DCwire® microcatheter, Tethys AS® aspiration catheter, and Fastunnel® balloon delivery catheter) and the successful launch of the newly approved YonFlow® flow-directed stent [1]

报名：首届全球眼科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 报名：首届全球骨科大会 | 奖项评选 合作伙伴征集：2025全球手术机器人大会 心未来 2025年3月26日， 沛 嘉医疗-B （09996.HK）发布截至2024年12月31日止年度业绩公告。 # 财报数据 报告期内，公司 收入达到6.15亿元人民币，同比增长39.53% 。其中，TAVR相关产品销售收入同比增长 40.1%至2.60亿元，占总收入的 42.2% ；神经介入产品销售收入同比增长39.1%至3.56亿元，占总收入的 57.8% 。 股东应占亏损 ：2024年股东应占亏损2.27亿元，同比收窄42.28%。 每股基本亏损 ：0.34元。 | 財務摘要 | | | | | --- | --- | --- | --- | | | 截至12月31日止年度 | | | | | 2024年 | 2023年 | 同比參動 | | | 人民幣千元 人民幣千元 | | | | 收入 | 615,483 | 441.126 | 39.5% | | 毛利 | 433.621 | 325.370 | 33.3% | | 銷售及分銷開支 | ...